English Court Queries EMA Primacy & Says Avastin Can Be Used In AMD

The English High Court has rejected attempts by Novartis and Roche to stop clinical commissioning groups from offering Avastin to wet AMD patients in a cost-containment move. In a development that has alarmed pharma firms, the court also questioned the exclusive role of the European Medicines Agency in marketing authorizations, saying that CCGs as well as the health technology assessment body, NICE, have competences in that area, and called on the UK regulator to review its guidance on off-label and unlicensed use.

Rejected
A court has rejected companies' attempts to stop the use of Avastin in wAMD in England

Roche and Novartis AG have been dealt another blow in their long-running European battle to stop Avastin (bevacizumab) being used for wet age-related macular degeneration (wAMD) in place of the more expensive Lucentis (ranibizumab) after the High Court said 12 clinical commissioning groups in northeast England could continue to offer Avastin to wAMD patients in order to save money, even though it is not approved for that use.

Under a policy adopted in 2017, the CCGs offered Roche's Avastin to certain patients with wAMD as the "preferred treatment...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet